Mind The Gap... We're late to this party, but a really good interview of David Grainger from Index Ventures was published in July of this year. We encourage you to read…
The new DiMasi estimates for R&D costs were published this week. You can get a PDF of their slides here, while Ed Silverman has a nice summary in the WSJ. According…
Earlier this week, The Economist travels over well-trod ground in an article on pharmaceutical industry M&A: It used to be all about achieving sheer scale, and building a broad portfolio…
Can't get there from here... We're back from another excellent BIO Europe convention. Held in Frankfurt, this year's version was attended by over 3,000 industry colleagues, experts, investors, and…
There's more to Wyoming than this. In Part One of his series, Dr. Garrett Lindemann discussed some of the challenges facing Wyoming as it grows its life science industry. In Part…
Is this the next major biotech cluster in the US? Wyoming? Yes, Wyoming. Why not? In the First of a Three-part series, our guest blogger Dr. Garrett Lindemann (@WyomingScience) discusses the…
The reports of my death have been greatly exaggerated. Mark Twain In July, we summarized the issue of companies acquiring other companies in tax-friendly countries. These so-called "inversions" were not…
Twenty Five. That's it. What are we talking about? Some of the data in yesterday's excellent post by Bruce Booth on Early Stage Venture Scarcity really caught us by surprise. What…
At Lacerta Bio, we're big believers in the therapeutic benefits of drug delivery in its many forms. Today, another drug delivery effort earned an FDA approval. In this case, it's…
This morning, California-based Avanir Pharmaceuticals announced that their combination of dextromethorphan HBr and quinidine sulfate (AVP-923) hit their Phase II endpoints in Alzheimer's Disease: Treatment with AVP-923 was associated…